RxDoctor Payments Data

Shahina Javeed, MD

Internal Medicine · Holiday, FLNPI 1457354474

Payments from drug & device makers

$1,278in general payments, 2019–2025

Across 16 payments — averaging $79.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$375
  • Lilly USA, LLC$190
  • Amgen$144
  • Boehringer Ingelheim$125
  • Novartis$125
  • Jazz Pharmaceuticals Inc.$100
  • plus $219 from 5 others

What the payments were for

  • Food & beverage$1,278100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,278 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$39,778
Medicare patients
81
Services billed
413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban161$111,330
XareltoRivaroxaban27$38,872
OzempicSemaglutide30$27,919
JardianceEmpagliflozin21$22,369
JanuviaSitagliptin Phosphate26$19,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$19,028
MounjaroTirzepatide14$17,210
Ondansetron Hcl24$12,416
Albuterol Sulfate HfaAlbuterol Sulfate168$6,404
Levothyroxine Sodium383$5,248
Atorvastatin Calcium694$5,050
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen222$4,249
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm40$3,996
Wixela InhubFluticasone Propion/Salmeterol18$3,815
LantusInsulin Glargine,hum.Rec.Anlog30$3,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$32$114,091184 claims
Boehringer IngelheimJardiance$125$22,36921 claims
GSKTrelegy Ellipta$375$19,02826 claims
Lilly USA, LLCMounjaro$190$17,21014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Holiday

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →